The pharmaceutical intermediates market size was valued at USD 35.56 billion in 2024 and is projected to reach USD 57.65 billion by 2034, registering a CAGR of 4.95% from 2025 to 2034. The increasing prevalence of diseases, along with higher healthcare expenditures, a growing demand for generic medications, and an uptick in API production are all contributing to the rising demand for pharmaceutical intermediates.
Pharmaceutical Intermediates Market Key Takeaways
· North America held a market share of 34.0% in 2024.
· By product, the bulk drug intermediates segment is expected to capture the biggest revenue share in 2024.
· By application, the analgesics segment is expected to acquire the largest share in 2024.
· By end user, the CROs/CMOs segment registered the maximum market share in 2024.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/5725
U.S. Pharmaceutical Intermediates Market Size and Growth 2025 to 2034
The U.S. pharmaceutical intermediates market size reached USD 9.3 billion in 2024 and is anticipated to be worth around USD 15.1 billion by 2034, poised to grow at a CAGR of 4.5% from 2025 to 2034.
North America Dominates the Pharmaceutical Intermediates Market. North America has been the key player in the pharmaceutical intermediates market due to the presence of some of the top drug companies and the advanced health care infrastructure and strong research and development capabilities. With the rise of new products and the increased approval of new drugs, the need for intermediates has risen consequently and contract manufacturing has become an important business model for the outsourcing of production.
U.S. Leads Pharmaceutical Intermediates Market with R&D Investment and Outsourcing Growth
United States Leads the pharmaceutical intermediates market in North America, driven by the ongoing R&D efforts and increased demand for complex intermediates in both traditional and biologic drug formulations. CMOs take up a lot of the contract manufacturing business, both to bring the cost of production down and to increase production, which, in turn, is essential for new and specialized intermediates.
· On January 16, 2024, Willow Biosciences partnered with Enterin Inc. to develop sustainable manufacturing processes for key intermediates and active pharmaceutical ingredients (APIs) for neurodegenerative treatments.
APAC Emerges as a Powerhouse in Pharmaceutical Manufacturing Driven by Skilled Workforce
The Asia Pacific region is emerging out as a powerhouse region in the pharmaceutical intermediates market which is being accelerated with the recent industrial revolution and also huge investments that are being made in each of the countries, China, South Korea, Australia etc. These factors are one of the primary reasons that are increasing the region’s pharmaceutical output and also its capability to attract major investments in the area of outsourced manufacturing.
· In 2024, Jiangsu Run'an Pharmaceutical Co. Ltd. participated in CPHI China to expand its international customer base and enhance global market presence.
The pharmaceutical industry has initiated a regime in which India is now ranked as the prime country in the APAC region for its manufacturing for the very first time. The only way the country has been able to create a market for itself is by hiring low-skilled workers and employing many scientists and engineers.
The Pharmaceutical Intermediates Market involves as a sector in the production and sale of chemical compounds utilized as precursors in the active pharmaceutical ingredient (APIs) manufacturing process. These intermediates are an important part of the drug formulation and production process. The market is driven by increasing demand for generic drugs, advancements in drug development, and the growing healthcare needs worldwide which lead to innovations in chemical processes and production efficiency.
The increasing emphasis on biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, presents substantial opportunities for suppliers in the pharmaceutical intermediates market. The rising demand for intermediates such as cell culture media, growth factors, and purification reagents—fueled by progress in biotechnology and personalized medicine, creates pathways for market growth.
Moreover, the growing international demand for medicines, which is driven by an increase in the average age of people and the rise in non-communicable diseases, represents a further expansion path.
AI has a significant role in the pharmaceutical ingredient market. It is making possible the development of drug products that have not existed before by prognosticating probable formulations and releasing mechanisms. AI is further utilized to optimize the efficiency of existing synthesis pathways, hereby leading to less waste and lower environmental impacts. Additionally, it helps to find new uses for old intermediates which widen their market application beyond the traditional ones.
Market Trends
· Growing Investment in R&D: Higher R&D spending that is targeted at new drugs is the reason for the need of traditional and complex intermediates in drug manufacturing that are used as a part of the production process. More efficient and time-consuming processes are being followed due to these new requirements that.
· Emphasis on Outsourcing: Companies attain cost savings and increase operating efficiency through strategic business relationships with Contract Manufacturing Organizations (CMOs). The knowledge of CMOs in the field of intermediate production allows pharmaceutical companies to free their departments to R&D and marketing exclusively.
· Dominance of Bulk Drug Intermediates: Bulk drug intermediates play a significant role in large-scale production of Active Pharmaceutical Ingredient (API), and they are particularly crucial in the case of generic drugs. Therapeutic areas of cancer and heart diseases have the largest number of patients who take generic drugs.
· Focus on Sustainable Production: Green chemistry and biocatalysis are the two up-and-coming (innovative) methods/types of pharmaceutical intermediate production. Acting as the "green" alternative, these ways result in less pollution and allow for more orderly production.
Report Scope of Pharmaceutical Intermediates Market
|
Report Coverage |
Details |
|
Market Size in 2025 |
USD 37.32 Billion |
|
Market Size by 2034 |
USD 57.65 Billion |
|
Growth Rate From 2025 to 2034 |
CAGR of 4.95% |
|
Base Year |
2024 |
|
Forecast Period |
2025-2034 |
|
Segments Covered |
Product, Application, and End User |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Key Companies Profiled |
The major players operating in the pharmaceutical intermediates market are BASF SE, Aceto Corporation, Sanofi SAIS, Chiracon GmbH, Yin-sheng Bio-tech Co. Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Vertellus Holdings LLC., Lonza Group. |
Segment Insights
Product Insights
The bulk drug intermediates that generated the maximum amount of revenue in 2024, were responsible for their widespread use in the production of Active Pharmaceutical Ingredients (APIs). These products are known for the therapeutic effects they provide as drug components. Government initiatives aimed at promoting bulk drug parks are expected to boost the growth of this sector through supportive policies and increased local manufacturing.
Customized intermediates are expected to be the segment with the highest growth as they consist of the adjustment of the molecules to reach certain curative effects. This section is becoming more attractive to the industry because thanks to it one can create the doses that would be best for the patient with the least side effects.
By Application Insights
Based on application, the analgesics segment accounted for around 31.0% of the global pharmaceutical intermediates market and is likely to remain its leadership due to the escalating occurrence of chronic diseases (arthritis, cancer, and cardiovascular conditions, etc.) leading to an increase in the demand for pain relief medications.
Conversely, the anti-cancer drugs segment is forecast to register a strong growth rate predominantly due to the upswing of cancer incidences that are taking place across the world. The segment will outstrip the others in the market with over 35 million new cases in 2050 according to the WHO.
By End User Insights
The CROs/CMOs segment is projected to dominate the global pharmaceutical intermediates market in 2024, driven by the swift growth and increasing impact of contract research and manufacturing organizations. This trend has greatly increased the demand for intermediates utilized in drug production and research, solidifying the segment's ongoing dominance.
Research laboratories are anticipated to be the fastest-growing segment, thanks to rising private investments in pharmaceutical research. This influx of funding for new drug development is expected to drive significant growth in the segment throughout the forecast period.
Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/5725
Related Report
· Pharmaceutical Analytical Testing Market - https://www.precedenceresearch.com/pharmaceutical-analytical-testing-market
· Pharmaceutical Intermediates Market - https://www.precedenceresearch.com/pharmaceutical-intermediates-market
· Active Pharmaceutical Ingredients Market - https://www.precedenceresearch.com/active-pharmaceutical-ingredient-market
Pharmaceutical Intermediates Market Top Companies
· BASF SE
· Chiracon GmbH
· Dishman Group
· Green Vision Life Sciences
· Midas Pharma GmbH
· Sanofi SAIS
· Vertellus Holdings LLC.
Pharmaceutical Intermediates Market Recent Development
·
In October 2024, Lonza extended its long-term collaboration with
leading global biopharmaceutical companies for the manufacturing of
antibody-drug conjugates, strengthening its position in the biopharmaceutical
sector.
·
On June 25, 2024, DSM-Firmenich launched CBtru®, an advanced
cannabidiol (CBD) drug product intermediate designed for oral solid delivery
formats, aiming to elevate patient health with innovative formulations.
· On March 22, 2024, YongNong announced the commencement of production for intermediates as part of its 50,000-ton L-glufosinate capacity, enhancing its agricultural product portfolio.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Pharmaceutical Intermediates Market
By Product
· Chemical Intermediates
· Bulk Drug Intermediates
· Custom Intermediates
By Application
· Analgesics
· Ant-inflammatory Drug
· Cardiovascular Drugs
· Anti-Diabetic Drugs
· Anti-Cancer Drugs
· Others
By End User
· Biotech and Pharma Companies
· Research Laboratory
· CMO/CRO
By Regional
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East and Africa (MEA)
Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/5725
USA: +1 804 441 9344
APAC: +61 485 981 310 or +91 87933 22019
Europe: +44 7383 092 044
Email: sales@novaoneadvisor.com
Web: https://www.novaoneadvisor.com/
You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 804 441 9344